Tutorial on Model Selection and Validation of Model Input into Precision Dosing Software for Model-informed Precision Dosing

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2023 Sep 29

PMID 37771190

Authors

Zachary L Taylor

Ethan A Poweleit

Kelli Paice

Katherine M Somers

Kathryn Pavia

Alexander A Vinks

Nieko Punt

Tomoyuki Mizuno

Sonya Tang Girdwood

Affiliations

Soon will be listed here.

Abstract

There has been rising interest in using model-informed precision dosing to provide personalized medicine to patients at the bedside. This methodology utilizes population pharmacokinetic models, measured drug concentrations from individual patients, pharmacodynamic biomarkers, and Bayesian estimation to estimate pharmacokinetic parameters and predict concentration-time profiles in individual patients. Using these individualized parameter estimates and simulated drug exposure, dosing recommendations can be generated to maximize target attainment to improve beneficial effect and minimize toxicity. However, the accuracy of the output from this evaluation is highly dependent on the population pharmacokinetic model selected. This tutorial provides a comprehensive approach to evaluating, selecting, and validating a model for input and implementation into a model-informed precision dosing program. A step-by-step outline to validate successful implementation into a precision dosing tool is described using the clinical software platforms Edsim++ and MwPharm++ as examples.

Citing Articles

Short, extended and continuous infusion of β-lactams: predicted impact on target attainment and risk for toxicity in an ICU patient cohort.

Smekal A, Swartling M, Furebring M, Giske C, Jonsson S, Lipcsey M J Antimicrob Chemother. 2025; 80(3):876-884.

PMID: 39847494 PMC: 11879237. DOI: 10.1093/jac/dkaf013.

A Review of Vancomycin, Gentamicin, and Amikacin Population Pharmacokinetic Models in Neonates and Infants.

Albanell-Fernandez M, Rodriguez-Reyes M, Bastida C, Soy D Clin Pharmacokinet. 2025; 64(1):1-25.

PMID: 39821208 PMC: 11762427. DOI: 10.1007/s40262-024-01459-z.

Development of a Population Pharmacokinetic Gabapentin Model Leveraging Therapeutic Drug Monitoring Concentrations.

Al-Zubaydi F, Wassef A, Kagan L, Brunetti L Pharmaceutics. 2025; 16(12.

PMID: 39771494 PMC: 11678411. DOI: 10.3390/pharmaceutics16121514.

Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.

Alasmari M, Albusaysi S, Elhefnawy M, Ali A, Altigani K, Almoslem M Saudi Pharm J. 2024; 32(12):102207.

PMID: 39697476 PMC: 11653594. DOI: 10.1016/j.jsps.2024.102207.

Barriers and Facilitators for Bringing Model-Informed Precision Dosing to the Patient's Bedside: A Systematic Review.

Dibbets A, Koldeweij C, Osinga E, Scheepers H, de Wildt S Clin Pharmacol Ther. 2024; 117(3):633-645.

PMID: 39659053 PMC: 11835426. DOI: 10.1002/cpt.3510.

References

Anderson B, Holford N . Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2007; 48:303-32. DOI: 10.1146/annurev.pharmtox.48.113006.094708. View

Peng L, Zhong X . Epigenetic regulation of drug metabolism and transport. Acta Pharm Sin B. 2015; 5(2):106-12. PMC: 4629221. DOI: 10.1016/j.apsb.2015.01.007. View

Bauer R . NONMEM Tutorial Part I: Description of Commands and Options, With Simple Examples of Population Analysis. CPT Pharmacometrics Syst Pharmacol. 2019; 8(8):525-537. PMC: 6709426. DOI: 10.1002/psp4.12404. View

Vinks A . Precision Medicine-Nobody Is Average. Clin Pharmacol Ther. 2017; 101(3):304-307. DOI: 10.1002/cpt.600. View

Sheiner L, Rosenberg B, Melmon K . Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972; 5(5):411-59. DOI: 10.1016/0010-4809(72)90051-1. View

Finney H, Newman D, Thakkar H, Fell J, Price C . Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. Arch Dis Child. 2000; 82(1):71-5. PMC: 1718178. DOI: 10.1136/adc.82.1.71. View

Brocks D, Hamdy D . Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring. Res Pharm Sci. 2021; 15(6):503-514. PMC: 8020855. DOI: 10.4103/1735-5362.301335. View

Paschos G, Baggs J, Hogenesch J, FitzGerald G . The role of clock genes in pharmacology. Annu Rev Pharmacol Toxicol. 2010; 50:187-214. DOI: 10.1146/annurev.pharmtox.010909.105621. View

Sinha Ray A, Haikal A, Hammoud K, Yu A . Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2016; 11(12):2132-2140. PMC: 5142072. DOI: 10.2215/CJN.05920616. View

10.

Marshall S, Burghaus R, Cosson V, Cheung S, Chenel M, DellaPasqua O . Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation. CPT Pharmacometrics Syst Pharmacol. 2016; 5(3):93-122. PMC: 4809625. DOI: 10.1002/psp4.12049. View

11.

Wicha S, Martson A, Nielsen E, Koch B, Friberg L, Alffenaar J . From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics. Clin Pharmacol Ther. 2021; 109(4):928-941. DOI: 10.1002/cpt.2202. View

12.

Mould D, Upton R . Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2013; 1:e6. PMC: 3606044. DOI: 10.1038/psp.2012.4. View

13.

Yafune A, Ishiguro M . Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: A use of bootstrap standard error. Stat Med. 1999; 18(5):581-99. DOI: 10.1002/(sici)1097-0258(19990315)18:5<581::aid-sim47>3.0.co;2-1. View

14.

Mould D, Upton R . Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e38. PMC: 3636497. DOI: 10.1038/psp.2013.14. View

15.

McGann P, Niss O, Dong M, Marahatta A, Howard T, Mizuno T . Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. Am J Hematol. 2019; 94(8):871-879. PMC: 6639795. DOI: 10.1002/ajh.25510. View

16.

Uges D . Plasma or serum in therapeutic drug monitoring and clinical toxicology. Pharm Weekbl Sci. 1988; 10(5):185-8. DOI: 10.1007/BF01956868. View

17.

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

18.

Tunblad K, Lindbom L, McFadyen L, Jonsson E, Marshall S, Karlsson M . The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J Pharmacokinet Pharmacodyn. 2008; 35(5):503-26. DOI: 10.1007/s10928-008-9099-z. View

19.

Keizer R, Ter Heine R, Frymoyer A, Lesko L, Mangat R, Goswami S . Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities. CPT Pharmacometrics Syst Pharmacol. 2018; 7(12):785-787. PMC: 6310898. DOI: 10.1002/psp4.12353. View

20.

Bauer R . NONMEM Tutorial Part II: Estimation Methods and Advanced Examples. CPT Pharmacometrics Syst Pharmacol. 2019; 8(8):538-556. PMC: 6709422. DOI: 10.1002/psp4.12422. View